Clinical validation in TNBC specimens reveals that aDMA‐VIMR64 (vimentin R64 aDMA) levels correlate with advanced tumor stages and poor patient prognosis, establishing this modification as a potential prognostic biomarker (Figure 3). Here, VIM is linked to neoplasm.